POPULARITY
9 episodes with cgrp
6 episodes with cgrp
3 episodes with cgrp
4 episodes with cgrp
6 episodes with cgrp
2 episodes with cgrp
4 episodes with cgrp
3 episodes with cgrp
8 episodes with cgrp
If your migraines suddenly feel more frequent, intense, or unpredictable in midlife, hormonal instability may be playing a bigger role than you realize.In this episode, you'll learn:
スタンフォード大学にて来春独立する東原幸起a.k.a兄者さんゲスト回。ドラッグボディビル、寄生虫感染に対する腸管の防御機構に関する最新論文の議論、など (8/19 収録)Show Notes (番組HP):連絡先->kouki.touhara★gmail.comStanford Medicine, Molecular and Cellular Physiology着任アナウンスページSteven Chu optical trappingで1997年ノーベル賞Tom Südhof synaptic transmission/vesicle release mechanismで2013年ノーベル賞。Brian Kobilka β2を含むGPCRの構造解析で2012年ノーベル賞 過去ゲストの加藤emeさんのポスドクアドバイザWu TsaiニューロAllenでやってたKeystone:Interoception: Neural Sensing and Control of Organ Function Rui CostaMark AndermannXin Sun生理学会大会、萩原が参加したのは2014年(91回)でしたグレリンの発見から臨床応用まで：古き良き発見の時代に モノトリはビハインドストーリーがわかりやすくてよい。人工リガンドとオーファン受容体がある状態でのリガンド(グレリン)探しで、脳をすり潰して片っ端からかけてったけど全然ダメで答えは胃でした、という流れ。受容体の構造を解きにいく段階でKobilkaが出てくるのもよい(萩)H1Bで10k払えどうこう東原兄弟ブログ 新 / 旧Deisseroth/Monje: Love means sharing the champagne東原デスブログ石井直方博士ライナス・ポーリング水がどうの：水が全身麻酔のメカニズム？説vitCでなんでも治る説ミロス:Miloš Šarčevミロス合宿ギシ(岸)さん:Big Hide, 山岸秀匡。オリンピア10回出場、マスターズ212級優勝経験を持つ日本人最強のボディビルダー。現在は競技を引退してラスベガスでパートナーのアイリス・カイル（ミス・オリンピア最多優勝を誇る最強の女性ボディビルダー）と共にパワーハウスジムを経営。閉所恐怖症でMRIがとれないハイパー・ジャイアントセット:複数種目をインターバルなしに連続でこなす方法。横川くん：横川直隆 ビビリで飛行機に乗れない212:212ポンド(100kg弱)以下の体重の階級。JINが肩トレでゲロ吐いた動画倉持くん：Ken Kuramochiエドワード加藤Lyft岩井ウイスキーのNHK朝ドラ:マッサンバイオステーション東原さん回David Julius実は5-HT1cもクローニングしてる Julius, Macdermott, Axel, and Jessel, 1988実はP2Y, P2X, 5-HT3もクローニングしてるおもしろ動物生物学: ヘビの赤外線感知、コウモリ赤外線感知、クモ毒、電気受容 パラサイト論文 (Touhara et al., 2026)Issac Chiu, CGRP: calcitonin gene-related peptideカルテクの岡先生Crypt-Villusの論文TRPA1:TRPA1をチャネルとしてクローニングしたのは実はArdem Patapotianです。ですが、このときは温度感知チャネルとして発見されています。後にDavidがマスタード類を感知する辛味レセプターだと発見します(東)EC細胞: Enterochromaffin cell, 腸クロム親和性細胞エレクトロファイル: 求電子剤5HTR3アンタゴニスト:Ondansetron/Zofranラクテースドーピング帰国発展：JSPS帰国発展。提出前にドラフトを交換してコメントして、無事両方通りました。さきがけのIP：（海外研究機関向け）契約締結に関する事前確認様式 (直pdfファイルリンク) 加藤emeさん回“神経修飾因子”の定義: このwikipediaの説明が個人的な理解に近い(萩)volume transmission 方散痛盲腸の役割樽野さんのラージポアチャネル 原著/総説AcuteなAChは虫を水でフラッシュする登さん回パワー (東)研究はさることながら、筋トレも一流で、ただただすごい。パワー。(筋トレが続かない藤)自分も東原兄弟ブログの一読者でした。最近筋トレしてないな… (脇)キーストンin Seattleのときに3人で飯に行ったのが前回の渉さんとだったというエモさ。各ホストが勝手に企画してるので本当に偶然(萩)
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the significant advancements and challenges that are shaping the future of drug development, regulatory landscapes, and industry innovations. Starting with a major milestone in personalized cancer therapy, the FDA has expanded Bayer's approval for Hyrnuo (zipalertinib) to include its use as a first-line treatment for HER2-mutant non-small cell lung cancer (NSCLC). This approval is based on promising Phase 1/2 clinical data, highlighting zipalertinib's role as a tyrosine kinase inhibitor targeting specific genetic mutations. This development is part of a broader trend towards precision medicine in oncology, allowing treatments to be specifically tailored to patients' genetic profiles. The potential impact on patient care is substantial, offering more effective treatment options for those with this particular HER2 mutation. In parallel, Johnson & Johnson's Imbruvica (ibrutinib) regimen has been endorsed by NICE for mantle cell lymphoma. These advancements represent a significant shift towards integrating precision medicine into oncology, aiming to improve outcomes by focusing on individual patient needs. On the business front, Samsung Biologics has secured a $262 million manufacturing deal with an unnamed European pharmaceutical company. This highlights an increasing demand for biologics manufacturing capabilities and reflects a growing reliance on contract development and manufacturing organizations (CDMOs) to meet complex therapeutic needs. Meanwhile, EMD Serono's acquisition of PostEra's AI-discovered fertility programs marks a pivotal move towards incorporating artificial intelligence in drug discovery, potentially revolutionizing women's health and fertility treatments. Clinical trial successes continue to drive momentum in the sector. AbbVie's Qulipta (atogepant) achieved its primary endpoint in a Phase 3 trial focused on menstrual migraines through CGRP receptor antagonism. This positions Qulipta as a promising new therapy within neurological disorders. Similarly, Rezera's Ruvonoflast met its primary endpoint in treating peripheral artery disease via NLRP3 inhibition, showcasing innovative anti-inflammatory approaches within cardiovascular medicine. Investment remains robust across the industry landscape. Frazier Life Sciences has successfully raised $1.1 billion to support small to mid-cap biotech companies, aiming to foster innovation and support emerging firms through critical phases of drug development. Additionally, CordenPharma's €80 million investment in enhancing aseptic fill-finish capacity illustrates strategic expansions within pharmaceutical manufacturing infrastructure. However, regulatory challenges persist. NICE's rejection of Gilead Sciences' lenacapavir due to cost concerns underscores ongoing debates around drug pricing and accessibility within healthcare systems. Furthermore, Biohaven Pharmaceuticals faces a partial clinical hold by the FDA on its epilepsy drug trial due to safety concerns. These instances highlight the rigorous scrutiny required throughout drug development processes. In response to these challenges, companies are increasingly adopting sophisticated strategies to navigate the evolving regulatory landscape. The "most favored nation" pricing policy in the U.S., designed to align domestic drug prices with those abroad, is prompting pharmaceutical firms to reassess their market strategies amid shifting economic conditions. On an optimistic note, Encoded Therapeutics has raised $275 million in Series F financing aimed at advancing gene therapies for conditions like Dravet syndrome. This substantial investment underscores confidence in gene therapy as a transformative approach for treating complex neurological and rare diseases. Finally, Ionis Pharmaceuticals achieved a breakthrough with its therapy approval for Alexander disease, illustrating the growing emphasis on targeting genetic disorders through precision medicine approaches. Such developments reflect both the dynamic nature of scientific innovation and the inherent challenges that accompany it. As these advancements unfold across various therapeutic areas and technological innovations continue to transform industry practices, it becomes increasingly clear that strategic planning and investment in research are crucial for translating scientific breakthroughs into tangible patient benefits. The ability of companies to innovate while ensuring compliance and economic viability will be pivotal as they strive to redefine treatment paradigms within this highly competitive sector. Thank you for joining us today on Pharma Daily. Stay tuned for more updates as we continue to bring you the latest insights from the ever-evolving pharmaceutical and biotech industries.Support the show
What happens when doctors misunderstand Ehlers-Danlos syndromes (EDS) and hypermobility spectrum disorders (HSD)? Sometimes the consequences go far beyond frustration or delayed treatment. In this episode of Bendy Bodies with the Hypermobility MD, Dr. Linda Bluestein is joined by Dr. Ina Stephens, Associate Director of the UVA Health EDS and Hypermobility Disorder Center, to answer listener questions about MCAS, gut health, circadian rhythm, migraine, pediatric hypermobility, and more. They also confront a disturbing reality for some families navigating poorly understood conditions: medical gaslighting, misdiagnosis, and inappropriate Munchausen-by-proxy referrals. Can you support a healthy gut microbiome with MCAS if fermented foods trigger symptoms? Drs. Bluestein and Stephens discuss the role of dietary fiber, polyphenol-rich foods, exercise, and thoughtful antibiotic use, including why the narrowest effective antibiotic may be preferable when treatment is necessary. They also explain why resetting a disrupted circadian rhythm involves more than simply going to bed earlier, and how morning light exposure can help shift the body's internal clock. Then the conversation turns to migraine management in hypermobile patients. Dr. Stephens shares her approach to supplements and medications, including magnesium glycinate, CoQ10, and CGRP-targeting medications such as ubrogepant (Ubrelvy,) while explaining why Botox (onabotulinumtoxin A) is not usually a first-line migraine treatment and may be problematic for people with significant craniocervical instability. The episode also tackles a question with major implications for the next generation: Should children be evaluated for hypermobile EDS earlier (hEDS)? Dr. Stephens explains how delayed recognition can contribute to years of orthopedic problems, psychological distress, inappropriate diagnoses, and missed opportunities for prevention and support. Finally, the episode closes with a Hypermobility Hack on low dose naltrexone (LDN): how it may work, why benefits can take time to appear, and why patience matters when evaluating whether it is helping. Takeaways: Could the wrong antibiotic choice create problems long after the infection is gone? Why might morning sunlight matter more than forcing yourself to go to bed earlier? When could Botox actually make headaches and neck symptoms worse in someone with hypermobility? How can missed or delayed recognition of hEDS in childhood affect orthopedic and mental health outcomes years later? What happens when physicians misunderstand EDS so profoundly that a family is suspected of fabricating illness? Why can low dose naltrexone seem like it is “not working” before it has had enough time to take effect? Want to learn more about the UVA EDS Center? For Appointments and Questions: RUVAEDSCenter@uvahealth.org UVA EDS: https://www.uvahealth.com/healthy-practice/advancing-care-through-ehlers-danlos-clinic UVA EDS FAQ: https://www.uvahealth.com/support/eds/faq UVA Pediatric Integrative Medicine: https://childrens.uvahealth.com/specialties/integrative-health Want more Dr. Linda Bluestein, MD? Website: https://www.hypermobilitymd.com/ YouTube: https://www.youtube.com/@bendybodiespodcast Instagram: https://www.instagram.com/hypermobilitymd/ Facebook: https://www.facebook.com/BendyBodiesPodcast X: https://twitter.com/BluesteinLinda LinkedIn: https://www.linkedin.com/in/hypermobilitymd/ Newsletter: https://hypermobilitymd.substack.com/ Shop my Amazon store https://www.amazon.com/shop/hypermobilitymd Dr. Bluestein's Recommended Herbs, Supplements and Care Necessities: https://us.fullscript.com/welcome/hypermobilitymd/store-start Thank YOU so much for tuning in. We hope you found this episode informative, inspiring, useful, validating, and enjoyable. Join us on the next episode for YOUR time to level up your knowledge about hypermobility disorders and the people who have them. Join YOUR Bendy Bodies community at https://www.bendybodiespodcast.com/. YOUR bendy body is our highest priority! Learn more about Human Content at http://www.human-content.com Podcast Advertising/Business Inquiries: sales@human-content.com Part of the Human Content Podcast Network Go http://www.AquaTru.com now for 20% off (your purifier) using promo code BENDY. FTC: This video is not sponsored. Links are commissionable, meaning I may earn commission from purchases made through links. Chapters: 00:00 EDS Starts Early00:34 Meet Dr Ina Stephens02:12 Fermented Foods MCAS02:39 Microbiome Support Basics10:47 Antibiotics Probiotics15:49 Medical Distrust CPS Risk29:31 Migraine Treatments Botox41:16 Feverfew Dosage Basics41:30 Avoiding Rebound Headaches43:12 CGRP Rescue Meds Explained44:51 Why Diagnose EDS Early49:05 Early Intervention and Prevention56:42 Parenting Tips and Clinic Access01:06:54 LDN Patience and Closing Resources Learn more about your ad choices. Visit megaphone.fm/adchoices
View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Brian Grosberg is a world-renowned headache specialist who joins Peter to provide a master class on the diagnosis and treatment of headache disorders. In this episode, Brian explains the distinction between primary and secondary headaches and breaks down the defining features of the "big three" primary headache types (migraine, cluster, and tension headache)—highlighting how often they are misdiagnosed and how they are treated. He explores the epidemiology of headaches, describing migraine as an invisible disease affecting about 12% of the population, disproportionately affecting women, while cluster headaches more often affect men. He discusses the major gap between demand for headache care and available specialists, and he offers advice on when to see a physician. Brian dives into the multifactorial nature and pathophysiology of migraine, including genetic and hormonal influences, neurovascular changes, and inflammatory signaling, and connects these mechanisms to modern therapies. Throughout the conversation, he emphasizes the individualized nature of headache disorders and the importance of a detailed headache diary. Brian shares practical strategies for treating headaches including lifestyle changes, medications, and neuromodulation devices. We discuss: Brian's interest in headaches and how Peter met Brian [2:15]; Differentiating the types of headaches: primary versus secondary headache and tension versus migraine headache [7:30]; The epidemiology and burden of migraine, its disproportionate affect on women, and the shortage of headache specialists [20:00]; Genetic susceptibility to migraine and the role of hormones [24:45]; Migraine triggers, the impact of hormones, and the importance of a headache diary [31:15]; The phases of a migraine: premonitory symptoms, aura, the headache itself, and the postdrome [38:15]; Tension headaches: symptoms, causes, and prevalence [41:45]; Cluster headaches: extreme pain, distinctive symptoms, and frequent misdiagnosis as a sinus infection or allergies [43:15]; Lifestyle interventions to prevent headaches [51:15]; Pharmacological treatments to prevent headaches [1:05:00]; What's known about the pathophysiology of migraines: neurovascular changes, release of neuropeptides, and inflammatory response [1:14:45]; CGRP antagonists for the treatment of migraines: large monoclonal antibodies and gepants [1:20:15]; Use of calcium channel blockers and Botox to treat cluster headache and migraine [1:28:30]; Drugs for the acute treatment of migraines [1:32:30]; Treatment of migraines with electrical stimulation devices [1:40:00]; Use of THC or cannabis to treat headaches [1:44:00]; What Brian wants people to know about headaches [1:45:45]; Brian's advice on when to see a doctor about headaches and how to prepare for that visit [1:49:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube
What if your bloating isn't separate from your migraine—but part of the same pattern?In this episode of Migraine Heroes Podcast, host Diane Ducarme explores the connection between digestive symptoms and migraine, and why the answer may go far beyond simply blaming certain foods.You'll learn:
What if your migraine pattern is becoming more frequent before you even realize it?In this episode of Migraine Heroes Podcast, host Diane Ducarme explores eight subtle signs that episodic migraine may be moving toward a more chronic pattern—from mild headache days and longer recovery periods to increasing sensitivity and more frequent medication use.You'll discover:
Send us Fan MailHow the nervous and immune systems communicate, using peptides and other signals, to regulate pain, itch, and inflammation.TOPICS DISCUSSED:Nociception & Pathogens: Sensory neurons detect bacterial toxins within seconds, enabling rapid host-defense coordination ahead of immune-cell recruitment.CGRP & neutrophils: Nociceptor-release the peptide CGRP, which blocks neutrophil (immune cell) recruitment; pathogens exploit this in necrotizing fasciitis and meningitis.Pain sensitization: Inflammation can lower neuronal thresholds for pain, which sometimes becomes a chronic problem.Gut barrier protection: CGRP from gut nociceptors drives goblet-cell mucus secretion, supporting the protective “weep and sweep” response.Skin-to-gut allergy priming: Early skin exposure to allergens plus scratching may promote food allergies.Vagus nerve circuits: Distinct vagal sensory neurons selectively suppress TNF or induce IL-10, allowing precise inflammatory control.Brain inflammatory memory: Insular neurons encode site-specific immune responses that can later be recalled by reactivating those circuits. The brain remembers past inflammatory events.ABOUT THE GUEST: Isaac Chiu, PhD is a professor in the Department of Immunology at Harvard Medical School. His lab studies nervous-immune system crosstalk in pain, itch, infection, and inflammatory disease.RELATED CONTENT:Article | Inflammation Regulation by Omega Fats: How High ω-6 Intake Impacts ω-3 LevelsSupport the showSupport my work:Good Chemistry: Personalized, science-based health consulting. Work with Dr. Nick Jikomes directly.Affiliate Partners: Visit this link to see my affiliate partners and get discounts codes for products & services to support health.For all the ways you can support my efforts.
For decades, migraine was explained to patients as a blood vessel problem: swelling, throbbing, treat it by shrinking things back down. That explanation is mostly a myth, and it may be part of why so many older treatments never worked.Dr. Fred Cohen is medical director of Headache Intervention and an assistant professor of medicine and neurology at the Icahn School of Medicine at Mount Sinai. He's one of the few headache specialists in the country trained in both internal medicine and headache medicine, has over 40 publications in journals including The Lancet and Cephalalgia, and has lived with migraine himself since his teens.In this conversation, you'll explore:Why migraine is a neuroinflammatory condition, not a vascular one, and why some medical schools still teach the outdated versionThe "broken thermostat" phenomenon of chronic sensitization, and how untreated migraine can convince your brain that constant pain is normalWhy only about 30% of people with migraine ever experience aura, and the surprising range of ways it can actually show upThe current treatment landscape, from triptans to CGRP therapies, Botox, neuromodulation devices, and what's coming nextWhy Dr. Cohen calls this the golden age of headache medicine, and what that means if you gave up on treatment years agoIf migraine has ever made you feel like your body was working against you, or like you'd already tried everything, this conversation will change how you see both.You can find Fred at: Website | Instagram | Episode TranscriptNext week, we're sitting down with Marisa Renee Lee to talk about why the tidy stories we tell ourselves about grief and resilience tend to fall apart, and what it actually looks like to build a life around pain instead of waiting to get past it. Be sure to follow Good Life Project wherever you get your podcasts so you don't miss any upcoming episodes!Check out our sponsors and resources: Visit Our Sponsor Page Hosted on Acast. See acast.com/privacy for more information.
The August 2026 recall showcases five incredible interviews highlighting recent advances in headache medicine. The episode begins with Dr. Patricia Pozo-Rosich discussing the latest advancements in headache medicine, focusing on key research findings from 2025. The episode continues with Dr. Jennifer Robblee discussing the latest consensus on refractory migraine. In the third episode of this series, Dr. Michael Eller discusses the implications of CGRP therapies in migraine treatment. The recall concludes with a two-part discussion featuring Drs. Tesha Monteith and Peter Goadsby, who highlight major developments in headache medicine presented at the 2026 AAN Annual Meeting. Podcast links: The Best of Headache Medicine from 2025: A Year in Review Refractory Headache Disorders, New Consensus, and Emergency Department Migraine Guidelines CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke Headache Medicine Highlights from the 2026 AAN Annual Meeting - Part 1 Headache Medicine Highlights from the 2026 AAN Annual Meeting - Part 2 Article links: Reaching International Consensus on the Definition of Refractory Migraine Using the Delphi Method 2025 Guideline Update to Acute Treatment of Migraine for Adults in the Emergency Department CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke Disclosures can be found at Neurology.org.
Could low blood pressure be quietly lowering your migraine threshold?In this episode of Migraine Heroes Podcast, host Diane Ducarme explores how reduced circulation, dizziness, fatigue, and brain fog may all be part of the same migraine picture. You'll learn why “normal” blood pressure does not always mean your body is getting the steady support it needs.You'll discover:
Quer saber como as novas descobertas médicas sobre o CGRP e a saúde periodontal estão revolucionando a prática clínica atual?Neste episódio do Afya News, analisamos as principais atualizações da medicina moderna que impactam o atendimento diário. Discutimos a elucidação do sistema trigeminovascular na enxaqueca e o papel dos bloqueadores do CGRP. Abordamos também a relação direta entre a doença periodontal e a calcificação da válvula aórtica. Por fim, debatemos os dados alarmantes da OMS sobre a projeção dos casos de câncer até 2050.O Afya News apresenta notícias da medicina com informação confiável e atualizada no seu tempo. Criado pela Afya, o maior hub de educação e soluções para a prática médica do Brasil, nosso propósito é transformar a saúde junto com quem tem a medicina como vocação.Fontes do episódio: https://portal.afya.com.br/podcasts/afya-news/21-07-2026
What if PCOS was never just about the ovaries, but about a deeper hormonal, metabolic, and nervous system pattern that could also be affecting your migraines?In this episode of Migraine Heroes Podcast, host Diane Ducarme explores the proposed shift from PCOS to PMOS, and why this new name may help migraine sufferers better understand symptoms that often feel disconnected, confusing, or random.You'll discover:
Up to 70% of people say they have sensitive skin — but is it really a diagnosis, or something else entirely? Dr. Patti Farris and Dr. Ted Lain break down the biology dermatologists are still trying to figure out. In this episode of the Science of Skin Podcast, Patti and Ted dig into a 15,000+ person global study on sensitive skin prevalence, and explore the science behind why skin reacts with no visible cause — covering TRPV1 and TRPA1 receptor activity, neuropeptide release (substance P, CGRP), and the connection to rosacea. They also unpack the exposome: how pollution, UV exposure, hormones, menopause, and the skin microbiome all play a role, including a deep dive into aryl hydrocarbon receptor (AHR) activation and inflammation. The episode closes with a new comparative cleanser study using D-Squame tape stripping and colorimetric index of mildness (SIM) testing, showing how Cetaphil Gentle Skin Cleanser performs against other "gentle" cleansers on the market.
Could high blood pressure be quietly adding pressure to your migraine brain?In this episode of Migraine Heroes Podcast, host Diane Ducarme explores how blood pressure, circulation, and nervous system stress may play a hidden role in migraine attacks. You'll learn why migraines may not be just a “head problem,” but a signal that your whole body needs deeper support.You'll discover:
To open the episode, Erica Marini, PharmD, discussed a roundup of FDA and research updates in neurology. She covered the shifting accelerated-approval pathway for AMT-130 (uniQure), a gene therapy for Huntington disease, and a similar back-and-forth for a Hunter syndrome gene therapy. She also noted an expanded indication for olezarsen (Tryngolza; Ionis Pharmaceuticals) in severe hypertriglyceridemia, a UK study linking hypotension to Alzheimer risk, and data suggesting shingles vaccination may lower dementia risk in Medicare beneficiaries. From the American Headache Society meeting, she highlighted phase 2b data on the TRPM8 agonist elismotrep (Kallyope), and the anti-PACAP antibody bocunebart (Lundbeck) for migraine, along with retrospective findings tying CGRP monoclonal antibodies to increased fracture risk and higher odds of spontaneous abortion in early pregnancy.The core interview featured Adrian Wong, PharmD, MPH, BCCCP; and Cayley Krkljes, PharmD, BCPS, of Beth Israel Deaconess Medical Center who discussed a systematic review published in Pharmacotherapy of clinically significant drug-drug interactions with phenobarbital and primidone. Wong and Krkljes described growing use of phenobarbital for alcohol withdrawal and note that health care professionals often underappreciate its interaction potential despite it being a well-known enzyme inducer. Key findings included an induction onset of 24 hours to 30 days and an offset of 2 to 8 weeks, findings that carry particular weight for transitions of care since inpatient dosing effects can persist well after discharge. The most clinically impactful interactions involved anticoagulants (warfarin and direct oral anticoagulants [DOACs]), methadone, and immunosuppressants, with approximately 85% of reviewed studies reporting some outcome impact. They also pushed back on recent social media claims that phenobarbital-DOAC interactions are not clinically relevant, pointing out methodological limitations in the studies behind that claim.The conversation moved into practical risk stratification: The guests described considering a patient's individual risk factors—such as recent thrombosis, transplant status, or opioid use disorder treatment with methadone or buprenorphine—before choosing phenobarbital over benzodiazepines for alcohol withdrawal. They outlined next steps for research, including studying real-world outcomes in high-risk medication combinations and surveying health care professional awareness of these interactions to identify education gaps. The episode closed with career advice for pharmacists interested in research—start small, find mentors, and leverage institutional resources.Key Takeaways: Phenobarbital's interaction risk is widely underrecognized. Despite growing use for alcohol withdrawal, phenobarbital's enzyme-inducing effects can persist for weeks after the last dose (onset 24 hours to 30 days; offset 2 to 8 weeks), making transitions of care a critical window for catching interactions—especially with anticoagulants, methadone, and immunosuppressants, which accounted for the most clinically impactful outcomes in the review. Not all "reassuring" data holds up under scrutiny. Wong and Krkljes challenged circulating social media claims that phenobarbital-DOAC interactions aren't clinically relevant, noting the studies behind those claims had methodological limitations, emphasizing the importance of evaluating primary literature rather than secondhand interpretations. Risk stratification should guide phenobarbital use. Individual patient factors (eg, recent thrombosis, transplant status, or opioid use disorder treatment with methadone or buprenorphine) should inform whether phenobarbital or a benzodiazepine is the safer choice for alcohol withdrawal management.
The migraine pain is gone… so why do you still feel exhausted, emotional, foggy, or completely drained afterward?In this episode of The Migraine Heroes Podcast, host Diane Ducarme explores the often-overlooked “migraine hangover” phase — also known as the postdrome stage. Blending neuroscience with holistic healing insights, this episode explains why your brain and nervous system may still be recovering long after the pain disappears.You'll discover:
Why do so many migraine attacks come with nausea, bloating, stomach discomfort, or digestive shutdown?In this episode of The Migraine Heroes Podcast, host Diane Ducarme explores the powerful connection between migraines and the gut-brain axis. Blending neuroscience with holistic healing perspectives, this episode reveals why nausea is not “just a symptom,” but often part of the migraine process itself.You'll discover:
We break down migraines as a neurologic condition with a real brain-based chain reaction, not a character flaw or a one-off “bad headache.” We share practical prevention habits, how to track triggers, and how acute and preventive migraine medications fit together so you can walk into your next visit prepared. • what makes a migraine different from other headache types • common and less common migraine presentations including aura and scary look-alikes • the five-step migraine chain reaction including CGRP and pain amplification • high-yield triggers like stress, sleep changes, skipped meals, hormones, smells, and weather shifts • consistency as the core prevention theme across sleep, exercise, eating, and stress • migraine diary basics to identify patterns and improve your neurologist visit • when headaches warrant a call to a clinician and what red flags to take seriously • acute treatment options including OTC meds, triptans, CGRP blockers, and anti-nausea meds • medication overuse headache risk when acute meds are used too often • preventive options including beta blockers, anti-seizure meds, antidepressants, and Botox You can find us on Threads, you could send us an email, or you can send us some fan mail. We still have that voice-based fan mail still waiting for that first fateful one. Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Jessica Ailani, MD, director of the MedStar Georgetown Headache Center, discusses emerging phase 2 data on bocunebart (Lundbeck), a PACAP-targeting monoclonal antibody being developed for migraine prevention. Presented at the 2026 American Headache Society Annual Meeting, findings from the PROCEED trial demonstrated efficacy in patients with episodic or chronic migraine who had previously failed 1 to 4 preventive therapies, including those considered treatment refractory. The conversation explores the efficacy and safety findings from PROCEED, pooled analyses from chronic migraine populations, and a separate study evaluating coadministration of bocunebart with ubrogepant. Ailani also discusses the potential role of PACAP-targeting therapies within the evolving migraine treatment landscape, considerations for future combination strategies, and key questions investigators will need to address as the program moves toward phase 3 development. Looking for more Headache & migraine discussion? Check out the NeurologyLive® Headache & migraine clinical focus page.Episode Breakdown: 1:10 – PROCEED trial efficacy in patients with prior preventive failures 5:10 – Safety and tolerability findings for bocunebart 6:30 – Coadministration data with ubrogepant and clinical implications 8:30 – Neurology News Network 10:50 – Rationale for combining PACAP and CGRP-targeted therapies 13:40 – Key considerations for future phase 3 development The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Topline Phase 2 CELIA Results Show Diranersen Misses Primary End Point in Early Alzheimer Disease FDA Grants Priority Review to Bayer's Asundexian for Secondary Stroke Prevention Dyne Submits BLA for Z-Rostudirsen in Exon 51 Skipping Duchenne Muscular Dystrophy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
In this episode of Talk Dizzy To Me, vestibular physical therapists Dr. Abbie Ross, PT, NCS and Dr. Danielle Tolman, PT sit down with neurologist Dr. Kristin Steenerson to unpack Persistent Postural Perceptual Dizziness, also known as 3PD or PPPD.If you feel dizzy, floaty, rocking, disoriented, or visually overwhelmed most days — especially in places like grocery stores, airports, busy restaurants, or while scrolling screens — this episode explains what may be happening in the brain and nervous system.Dr. Steenerson breaks down the diagnostic criteria for 3PD, why symptoms can continue even after the original vestibular problem improves, how 3PD overlaps with vestibular migraine, and why treatment often requires a combination of education, vestibular therapy, medication, cognitive strategies, lifestyle support, and gradual exposure.This conversation also addresses why 3PD is sometimes misunderstood, how hypervigilance plays a role, and why there is real hope for recovery and improved quality of life. Hosted by:
Migraines are often dismissed as “just a bad headache,” but they can be much more serious and disruptive. So what actually causes migraines, and when should someone stop trying to push through the pain?In this episode of Baptist Health Talk, host Sandra Peebles speaks with Dr. Maria Vera Silva, neurologist at Baptist Health Miami Neuroscience Institute, and Dr. Andrew Forster, internal medicine physician at Baptist Health Primary Care, about what migraines are, how they affect the brain, and why treatment is not one size fits all.In this conversation, they discuss: Why migraines are considered a neurologic disease How migraines differ from regular headaches Common triggers, including stress, hormones, sleep changes, foods and weather The connection between migraines and mental health Treatment options, including anti inflammatories, triptans, CGRP inhibitors and Botox What to know about viral migraine “hacks” on social media When migraine symptoms should prompt a visit to a doctor Migraines can interfere with work, school, family life and everyday activities. Understanding the signs, triggers and treatment options can help patients get the right care sooner.For more health and wellness information, visit Baptist Health South Florida's resource blog: baptisthealth.net/newsHost:Sandra PeeblesAward-Winning JournalistGuest:Maria Andreina Vera Silva, M.D. NeurologistBaptist Health Miami Neuroscience InstituteAndrew Forster, M.D. Internal Medicine Physician Baptist Health Primary CareIf you found this episode helpful, you may also enjoy:A 'Heads Up' on Migraine & Headache Disorders
Drs. Chandwani and Kuruvilla explain that migraine and facial pain often share trigeminal system mechanisms, leading to frequent misdiagnosis as dental, musculoskeletal, or sinus problems, possibly resulting in unnecessary procedures. The speakers emphasize CGRP-targeted therapies, careful mechanism-based diagnosis, and multidisciplinary collaboration across neurology, orofacial pain, physical therapy, and behavioral health to improve outcomes for patients with complex facial pain and migraine presentations.
In this episode, I'm talking about something I'm not hearing many people in the migraine space discuss openly, Botox as a preventative treatment for chronic migraines. My goal isn't to scare you or tell you what to do. My goal is to make sure you have the full picture before you make a decision about what goes into your body. I explain what Botox actually is, how it works in your body, why the migraine protocol uses far higher doses than cosmetic Botox, and the long-term concerns I have around muscle atrophy, neck function, CGRP, and your body's overall toxic load. I also share why I believe neck pain is often a symptom of migraines rather than the cause, and what I recommend focusing on instead if you want real, long-term healing. If you haven't yet listened to my previous episode on trigger point injections, I highly recommend pairing these two together, they build on each other and give you a fuller understanding of what's really driving your chronic migraines.Check out the podcast episode about trigger point injections: Trigger Point Injections and Migraines. What Nobody Tells YouIf you're ready to address the root drivers of your migraines, you can book a free consultation at the link below: https://www.drlesliecisar.com/apply Free Training: 5 Proven Steps to Being Migraine Free (Even if you think you've already tried everything.) https://www.drlesliecisar.com/5SHMN Connect with us: Website: https://www.drlesliecisar.com/ Free Facebook Group: Healing Migraines Naturally, with Leslie Cisar, ND Ready to try something radically different that actually works? Read more about my approach here: https://www.drlesliecisar.com/map In health,Dr. Leslie Cisar
Drs. Kuruvilla and Chandwani discuss migraine as a key women's health issue driven largely by estrogen fluctuations across a woman's lifespan, influencing CGRP, serotonin, sleep, and comorbid pain conditions from menstruation through perimenopause and menopause. These experts emphasize individualized, interdisciplinary care that combines CGRP-targeted preventives, hormonal strategies, integrative medicine (eg, acupuncture, supplements), and lifestyle and sleep optimization to improve quality of life.
Every spring, something shifts. The air changes, your body reacts… and your migraines may quietly follow.In this episode of Migraine Heroes Podcast, host Diane Ducarme explores the often-overlooked connection between pollen allergies and migraine patterns. What you may dismiss as “just hay fever” could be placing hidden stress on your nervous system—and lowering your threshold for migraine attacks.Blending neuroscience with a holistic lens, this episode helps you understand how seasonal changes influence your brain, your immune system, and your pain.You'll discover:
What if preventing migraines didn't require drastic changes—but small ones repeated consistently?In this episode of Migraine Heroes Podcast, host Diane Ducarme explores how the concept of atomic habits can transform migraine prevention. While many people search for a single trigger, migraine brains often react to the accumulation of tiny daily stresses: poor sleep, dehydration, skipped meals, emotional strain, or screen overload—until the brain crosses its migraine threshold.Inspired by the philosophy of small, consistent actions popularized in behavioral science, Diane explains how tiny daily habits can gradually strengthen your nervous system and help stabilize the sensitive migraine brain. By blending neuroscience, lifestyle medicine, and practical experience from working with migraine sufferers, this episode reveals why consistency beats intensity when it comes to protecting your brain.You'll learn:
What are your options for migraine prevention, and how do you choose the right one? In Part 2 of this two-part Spotlight on Migraine series, host Molly O'Brien and headache specialist Dr. Jessica Ailani dive into the full range of migraine prevention treatments available today. Dr. Ailani breaks down lifestyle modifications, neuromodulation, CGRP-targeted treatments, onabotulinumtoxinA, supplements, and more. She discusses combination treatment and options for menstrual migraine. With good migraine prevention, you can stop chasing attacks and gain back some control over attack frequency. Be sure to listen to Part 1 for a discussion on when to start prevention and how to measure success: https://www.migrainedisorders.org/pod... Read the transcript at: https://www.migrainedisorders.org/podcast/s8e4-migraine-preventive-options/ *The contents of this podcast are intended for general informational purposes only and do not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. AMD and the speaker do not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.
You've heard it before: “Stress triggers migraines.” But here's what most people don't realize , not all stress is created equal.In this episode of Migraine Heroes Podcast, host Diane Ducarme breaks down the five core faces of stress and reveals how each one activates a different pathway in your brain and body. Because the stress of pressure and performance does not impact your nervous system the same way as grief, overstimulation, or emotional tension.When you identify which stress pattern is driving your attacks, you move from vague advice to precise action.In this episode, you will learn:
Dr. Jessica Ailani and Dr. Richard Lipton discuss future advancements in headache medicine. Show transcript: Dr. Jessica Ailani: Hello and welcome to the Neurology Minute. I'm Jessica Ilani from Georgetown Headache Center in Washington, DC. In the neurology podcast with Richard Lipton from the Montefiore Headache Center, we'll be discussing the latest clinical trials in headache medicine, where our field is going, where it's been, and you'll get lots of great advice on thinking through a clinical trial, what the advances have been, where their pitfalls have been, and really how to think of both positive and negative trials. So Richard, what are you most looking forward to when it comes to new treatment targets within headache? Dr. Richard Lipton: First, let me say that I'm sure most know about the eight CGRP targeted treatments have been approved for migraine, both as acute and preventive treatments. And it's very clear that those treatments have had incredible benefits for our patients and have really improved headache practice. There's another neuropeptide target also targeted by monoclonal antibodies called PACAP or pituitary adenolyte cyclase activating polypeptide. This peptide is also a potent vasodilator involved in pain signaling like CGRP. While CGRP is primarily linked to sensory pathways, PACAP is found in parasympathetic ganglia. And for that reason, it may have a special role in headaches associated with cranial autonomic symptoms. And that includes both migraine, which commonly has cranial autonomic symptoms and also cluster headache. There's a recent randomized trial published in New England Journal showing that a monoclonal antibody targeting PACAP reduced monthly migraine day frequency and was beneficial in people who failed to respond to CGRP inhibitors. So that's at least one area that I'm hopeful about. Dr. Jessica Ailani: So Richard, thank you so much. I hope you have a few moments and listen to our full podcast that'll tell you a lot more about the future of headache medicine.
In part one of this series, Dr. Tesha Monteith and Dr. Jennifer Robblee discuss an international consensus definition for refractory migraine and why clearer criteria are needed. Show citations: Robblee J, Minen MT, Friedman BW, Cortel-LeBlanc MA, Cortel-LeBlanc A, Orr SL. 2025 Guideline Update to Acute Treatment of Migraine for Adults in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies. Headache. 2026;66(1):53-76. doi:10.1111/head.70016 Robblee J, Khan FA, Marmura MJ, et al. Reaching International Consensus on the Definition of Refractory Migraine Using the Delphi Method. Cephalalgia. 2025;45(9):3331024251367767. doi:10.1177/03331024251367767 Show transcript: Dr. Tesha Monteith: Hi, this is Tesha Monteith with the Neurology Minute. I've just been speaking with Jennifer Robblee about her exciting work defining refractory migraine with an international consensus, as well as her work with the American Headache Society on a guideline update for parental pharmacotherapies for migraine in the emergency department. Hi, Jennifer. Thanks again for coming on our Neurology Minute. Dr. Jennifer Robblee: Thank you so much for having me. I'm delighted to be here. Dr. Tesha Monteith: You've done a lot of work in the area of refractory migraine. Why don't you tell us why you felt there need to be clarification on the definition? Dr. Jennifer Robblee: Well, this is a patient population that I'm really passionate about. There's not enough research out there. We don't really know who these patients are, why they're not responding to treatment, and we don't know how to help them because we have no guidelines, obviously, since they're refractory to what we use for treating. So I thought it was really good to get an international group to standardize our definition and hopefully help move the research forward. Dr. Tesha Monteith: Why don't you tell us a little bit about the consensus definition Dr. Jennifer Robblee: So we came up with an international consensus definition for refractory migraine that was laid out the same way that migraine is, say, laid out in the ICHD-3 diagnostic manual, if you want to call it that. So we have different criteria on. So criterion A basically allowed for it to be episodic or chronic migraine. Criterion B had three subcriteria, so you needed to have at least two out of three of severe to very severe disability and/or a constant background headache and/or at least eight monthly migraine days. Criterion C was about the lack of response to treatment. And basically it says that you needed to have failure of all medication categories, and there is an extra one for an other in case any new treatments emerge before the diagnostic criteria get updated. And what we considered a, quote, unquote, failure was that you did not have a 50% improvement in monthly migraine days, or you had intolerable side effects, or you had an absolute contraindication. There is a caveat that you need to have at least four true lack of efficacies. And then the CGRP monoclonal antibody or gepant category and the onabotulinumtoxin toxin category both had to be a true lack of response. And of course, there's a criterion B to say that this should not be from another diagnosis. Dr. Tesha Monteith: Thanks so much, Jennifer.
"CGRP Targeting Treatments: A Valuable Addition to the Migraine Armamentarium." From ASRA Pain Medicine News, February 2026. See the original article at www.asra.com/february26news for figures and references. This material is copyrighted.Support the show
Dr. Tesha Monteith and Dr. Patricia Pozo-Rosich discuss the latest advancements in headache medicine, focusing on key research findings from 2025. Show transcript: Dr. Tesha Monteith: Hi, this is Tesha Monteith with the Neurology Minute. Welcome to our 2026 Headache Medicine Series. I've just been speaking with Patricia Pozo-Rosich about all of the exciting advances in headache medicine in 2025. For a minute, why don't you summarize some of the key advances in headache medicine research? Dr. Patricia Pozo-Rosich: I think that we have good news in headache. We are currently phase two trials for two or three different compounds, anti-part two, packup and new toxins. So we are actually, I think, excited to find out the phase 2B trial results and phase three. So well, that's something that I think is worth mentioning. Then I think it is important to remember that we have new data coming from real world evidence with long-term use of anti CGRP therapies. We also have data that shows that anti CGRP therapies are useful for patients with migraine and major depressive disorder, as well as as children. Finally, I think that it is very important to remind everyone that there are new papers on practice recommendations around the world on how we have to treat our patients with migraine, and that is related both to the acute and preventive therapies. And finally, couple of position statements that have been written by the International Hague Society that strive to improve the quality of how migraine individuals are treated, and that really conveys a paradigm shift where we probably should be starting preventive therapy sooner than later. Dr. Tesha Monteith: Great. Thank you so much for that quick summary. And please check out the Full Headache Medicine series. I appreciate talking to you, Patricia, and look forward to discussing more highlights next time. Dr. Patricia Pozo-Rosich: Thank you, Tisha. See you very soon. Dr. Tesha Monteith: And thank you for listening to the Neurology Minutes.
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Amaal Starling, MD, FAHS, FAAN, joins the podcast to provide clinical perspective on the INFUSE real world study evaluating IV eptinezumab in adults with migraine who previously found one or more CGRP preventive options ineffective, based on data presented at the 2026 Headache Cooperative of the Pacific Annual Conference. Starling, an associate professor of neurology at Mayo Clinic College of Medicine and a study author on INFUSE, discusses how clinicians should interpret the magnitude of benefit in a high burden population and why IV delivery, including rapid and consistent bioavailability, may help explain early and sustained response. The conversation also explores what the findings suggest for real world care and treatment sequencing, how migraine trials can better capture patient experience through outcomes like good days and PGIC, and what precision medicine research could look like next as the field pushes toward predictive modeling and individualized treatment selection.Looking for more Headache & Migraine discussion? Check out the NeurologyLive® Headache & Migraine clinical focus page.Episode Breakdown: 1:20 – Interpreting real world response after prior CGRP preventive failure 4:25 – Mechanistic reasons IV eptinezumab may drive early sustained benefit 6:25 – Clinical implications for earlier, more robust treatment sequencing 8:50 – Neurology News Network 11:20 – Integrating good days and Patient Global Impression scales into migraine trial design 15:30 – Future studies needed to advance precision migraine care The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Fenebrutinib Achieves Primary End Point in Phase 3 Head-to-Head Trial vs Teriflunomide in Relapsing MS Praxis Submits NDAs for Ulixacaltamide in Essential Tremor and Relutrigine in SCN2A/SCN8A Developmental Epileptic Encephalopathies Efgartigimod Meets Primary End Point in Phase 3 ADAPT OCULUS Study of Ocular Myasthenia Gravis Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
Drs. Ailani and Dougherty discuss onabotulinumtoxinA, a cornerstone treatment for chronic migraine, which reduces headache days and disability when given regularly with the PREEMPT protocol. They emphasize its unique benefits and how it pairs with CGRP therapies, oral preventives, and lifestyle changes for individualized care.
In part one of this two-part series, Dr. Tesha Monteith and Dr. Andrew Hershey summarize findings from the SPACE trial evaluating fremanezumab in adolescents and children with migraine. Show citation: Hershey AD, Szperka CL, Barbanti P, et al. Fremanezumab in Children and Adolescents with Episodic Migraine. N Engl J Med. 2026;394(3):243-252. doi:10.1056/NEJMoa2504546 Show transcript: Dr. Tesha Monteith: Hi, this is Tesha Monteith with the Neurology Minute. I'm here with Andrew Hershey, Professor of Pediatrics and Director of the Division of Neurology at Cincinnati Children's and the Children's Headache Center. We're here talking about his new paper published in the New England Journal of Medicine, Fremanezumab in Children and Adolescents with Episodic Migraine. Andrew, thank you for being on our Neurology Minutes. Dr. Andrew Hershey: Thank you for inviting me. Dr. Tesha Monteith: Can you summarize the findings of the space trial investigating Fremanezumab for adolescents and children with migraine? Dr. Andrew Hershey: This is one of the four monoclonal antibodies against CGRP, or it's this receptor that had been proven effective for adults. And it's the first one, the formazepam, that's been able to report its effectiveness in children and adolescents with less than 15 headache days per month. This study looked at over 200 children adolescents that were in a double-blinded randomized placebo controlled study. And reached its primary, as well as its secondary endpoint of a reduction compared to placebo. And the number of attacks of migraine per month, as well as a greater than 50% reduction in the number of headache attacks per month, with minimal to no side effects, the most notable side effect being injection site erythema. Dr. Tesha Monteith: Great. Thank you so much for providing that update. Do check out the full podcast for more details about his paper and the treatment of migraine in children and adolescents. This is Tesha Monteith. Thank you for listening to the Neurology Minute.
Dr. Tesha Monteith and Dr. Michael Eller discuss the implications of CGRP therapies in migraine treatment, particularly for patients with vascular risk factors or a history of stroke. Show citation: Eller MT, Schwarzová K, Gufler L, et al. CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke: A Review. Neurology. 2025;105(2):e213852. doi:10.1212/WNL.0000000000213852 Show transcript: Dr. Tesha Monteith: Hi, this is Tesha Monteith with the Neurology Minute. I've just been speaking with Michael Eller from the Department of Neurology Medical University of Innsbruck, Austria on the neurology podcast on his paper, CGRP Targeted Migraine Therapies in Patients with Vascular Risk Factors or Stroke: A Review. Hi, Michael. Dr. Michael Eller: Hello. Dr. Tesha Monteith: Why don't you summarize your general approach to use of CGRP targeted therapies in patients that might be at risk for vascular events when considering safety? Dr. Michael Eller: Yeah. About acute vascular events, we should stop CGLP targeted drugs immediately. When we come to post-stroke, we should reassess the necessity of these targeted treatments after recovery. We suggest a minimum of three months pause after ischemic stroke to allow early recovery and remodeling, and then restart only after individualized benefit risk review. In high-risk primary prevention, so no stroke yet, but elevated risk, if the patients are 65 years or older with established cardiovascular disease, we should prefer traditional preventives. And if CGLP targeted therapy is essential, we should consider Gepants cautiously due to their shorter half lives. We should avoid CGLP targeted treatments in small vessel disease, distal stenosis, Raynaud's phenomenon, and uncontrolled hypertension. For acute migraine treatment, we can consider gepants or ditans as alternatives to triptans and NSAIDs in relevant stroke risk or post-stroke patients, individualized to comorbidities. Dr. Tesha Monteith: Great. And we should say that the label updates include hypertension and Raynaud's phenomenon as potential vascular complications. Otherwise, these are more theoretical risks based on what we know about CGRP. Dr. Michael Eller: Yes, I totally agree because large studies did not show any elevated cardiovascular risk signals. And for post-marketing databases, we did not see any elevated cardiovascular risk so far. However, in pre-clinical settings, studies showed large infarct size in pretreated mice. Dr. Tesha Monteith: Great. Well, thank you again for doing this work. It was a phenomenal read and congratulations. Dr. Michael Eller: Thank you. Dr. Tesha Monteith: This is Tesha Monteith. Thank you for listening to the Neurology Minute.
Dr. Tesha Monteith talks with Dr. Michael Eller about the implications of CGRP therapies in migraine treatment, particularly for patients with vascular risk factors or a history of stroke. Read the related article in Neurology®. Disclosures can be found at Neurology.org.
Estima-se que em torno de 15% da população mundial sofra de enxaqueca, com maior prevalência nas mulheres - e muitos sintomas, tais como aura, além de hipersensibilidade à luz, ao som e ao cheiro... Afinal, o que a ciência tem a dizer sobre o tema?Confira o papo entre o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.>> OUÇA (60min 43s)Convidado: Dr. Fabiano Moulin de MoraesMédico neurologista pela Escola Paulista de Medicina da UNIFESP, onde é preceptor da residência em Neurologia. Membro titular da Academia Brasileira de Neurologia, Professor da Casa do Saber e Especialista em neurologia da cognição e do comportamento. Participou do Naruhodo Entrevista 48.* Naruhodo! é o podcast pra quem tem fome de aprender. Ciência, senso comum, curiosidades, desafios e muito mais. Com o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.Edição: Reginaldo Cursino.http://naruhodo.b9.com.br*APOIO: INSIDERIlustríssima ouvinte, ilustríssimo ouvinte do Naruhodo, janeiro é tempo de recomeços - e o recomeço mais importante é o momento em que acordamos, todos os dias.Afinal, a escolha da manhã muda tudo:- Vestir a roupa de treino assim que acorda — mesmo treinando só à tarde — aumenta a chance de cumprir a meta.- Colocar uma peça inteligente para trabalhar ou criar conteúdo te coloca instantaneamente em modo produtivo e confiante.- Mesmo para ficar em casa, trocar o pijama por um look confortável e bonito muda o humor, a energia e a presença.Ou seja: a Insider entra no seu ritual matinal e acompanha sua rotina com naturalidade.Então use o endereço a seguir pra já ter o cupom NARUHODO aplicado ao seu carrinho de compras: são 10% de desconto, ou 15% de desconto caso seja sua primeira compra.>>> creators.insiderstore.com.br/NARUHODOOu clique no link que está na descrição deste episódio.E bons recomeços pra você!INSIDER: inteligência em cada escolha.#InsiderStore*REFERÊNCIASMigraine Triggers: An Overview of the Pharmacology, Biochemistry, Atmospherics, and Their Effects on Neural Networkshttps://pmc.ncbi.nlm.nih.gov/articles/PMC8088284/Migraine and cognitive dysfunction: a narrative reviewhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11657937/Structural and Functional Brain Changes in Migrainehttps://pmc.ncbi.nlm.nih.gov/articles/PMC8119592/Migraine: Multiple Processes, Complex Pathophysiologyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC4412887/Migraine management: Non-pharmacological points for patients and health care professionalshttps://www.degruyterbrill.com/document/doi/10.1515/med-2022-0598/htmlIs there a causal relationship between stress and migraine? Current evidence and implications for managementhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8685490/The Global Burden of Migraine: A 30-Year Trend Review and Future Projections by Age, Sex, Country, and Regionhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11751287/Practical issues in the management of sleep, anxiety, and mood disorders in primary headacheshttps://pmc.ncbi.nlm.nih.gov/articles/PMC12221693/Differentiating Visual Symptoms in Retinal Migraine and Migraine With Aura: A Systematic Review of Shared Features, Distinctions, and Clinical Implicationshttps://pmc.ncbi.nlm.nih.gov/articles/PMC12380025/Current Trends in Pediatric Migraine: Clinical Insights and Therapeutic Strategieshttps://pmc.ncbi.nlm.nih.gov/articles/PMC11940401/Migrainehttps://www.nejm.org/doi/10.1056/NEJMra1915327Pratice guideline update summary: Acute treatment of migraine in children and adolescentshttps://www.neurology.org/doi/10.1212/WNL.0000000000008095Migraine aura as an artistic resource https://nah.sen.es/vmfiles/vol13/NAHV13N22025102_115EN.pdfMigraine aura as artistic inspiration.https://pmc.ncbi.nlm.nih.gov/articles/PMC1838881/Migraine as a source of artistic inspirationhttps://neuro.org.br/pdfs/RBN-59/RBN-594-DEZEMBRO/RBN-594-DEZEMBRO.pdf#page=44Migraine and risk of all-cause mortality and specific cause mortality: a systematic review and meta-analysishttps://pmc.ncbi.nlm.nih.gov/articles/PMC12534955/Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysishttps://pmc.ncbi.nlm.nih.gov/articles/PMC11409395/The impacts of migraine on functioning: Results from two qualitative studies of people living with migrainehttps://pmc.ncbi.nlm.nih.gov/articles/PMC10922598/Exploring the Hereditary Nature of Migrainehttps://pmc.ncbi.nlm.nih.gov/articles/PMC8075356/Transient receptor potential melastatin 8 (TRPM8) is required for nitroglycerin and calcitonin gene-related peptide induced migraine-like pain behaviors in micehttps://pmc.ncbi.nlm.nih.gov/articles/PMC9519811/Association between weather conditions and migraine: a systematic review and meta-analysishttps://link.springer.com/article/10.1007/s00415-025-13078-0Evaluation of Green Light Exposure on Headache Frequency and Quality of Life in Migraine Patients: A Preliminary One-way Cross-over Clinical Trialhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8034831/CGRP — The Next Frontier for Migrainehttps://www.nvvg.nl/files/3306/CGRP%20—%20The%20Next%20Frontier%20for%20Migraine.pdfDigital Media Use in Adolescents with Migraine: A Topical Reviewhttps://link.springer.com/article/10.1007/s11916-025-01444-6Placebo Response in Acute and Prophylactic Treatment of Migrainehttps://www.neurologic.theclinics.com/article/S0733-8619(25)00068-4/abstractCalcitonin Gene–Related Peptide Inhibitors and Cardiovascular Events in Patients With Migrainehttps://www.neurology.org/doi/abs/10.1212/WNL.0000000000214479?casa_token=WccpvEByt0MAAAAA:LKbxQClihNe2WsrHRKBmteHftcUECeozPKYcnSQPjsBA0hlEvKExc2DvBgn-J5WwWyudd3QV1nluWwInsights from triggers and prodromal symptoms on how migraine attacks start: The threshold hypothesishttps://journals.sagepub.com/doi/10.1177/03331024241287224Elucidating the susceptibility genes between insomnia and migraine by integrating genetic data and transcriptomeshttps://link.springer.com/article/10.1186/s10194-025-02249-zThe experience of neck pain in people with migraine: A qualitative studyhttps://www.sciencedirect.com/science/article/pii/S1413355525003922?casa_token=9ct7RuiXWIgAAAAA:Sxlqh2wKO3-2l4ig9hzuXb92eJtttlM1Mdd3EId-5BfNQ2J8kpTn2iCd3tr6a0l58kyqDTDR7wThe impact of pain on memory: a study in chronic low back pain and migraine patients https://academic.oup.com/braincomms/article/8/1/fcaf486/8376909Migraine as a dynamic continuum during the life coursehttps://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00441-7/abstractNaruhodo #447 - O que é AVC e como evitá-lo? #TodosPeloPirullahttps://www.youtube.com/watch?v=vRu9cet1TWMNaruhodo #236 - Por que temos dor de cabeça?https://www.youtube.com/watch?v=q8FtXVlSz1INaruhodo #345 - Por que às vezes sentimos as dores dos outros?https://www.youtube.com/watch?v=mKdMBCqy6XANaruhodo #145 - Por que a cabeça dói quando tomamos gelado?https://www.youtube.com/watch?v=qjq2Ds6YB-cNaruhodo #165 - Quando tomo antidepressivos continuo sendo eu mesmo?https://www.youtube.com/watch?v=dWyfUyHUiA4Naruhodo #62 - Existem doenças psicossomáticas?https://www.youtube.com/watch?v=etuFYdCAKe4Naruhodo #288 - Por que existe a menopausa?https://www.youtube.com/watch?v=3Ewwdi2guWgNaruhodo #339 - Por que as coisas parecem girar quando estamos bêbados?https://www.youtube.com/watch?v=YmK1Yq0mwW8Naruhodo #398 - Jejum intermitente funciona?https://www.youtube.com/watch?v=lTkWGFFkOLo*APOIE O NARUHODO!O Altay e eu temos duas mensagens pra você.A primeira é: muito, muito obrigado pela sua audiência. Sem ela, o Naruhodo sequer teria sentido de existir. Você nos ajuda demais não só quando ouve, mas também quando espalha episódios para familiares, amigos - e, por que não?, inimigos.A segunda mensagem é: existe uma outra forma de apoiar o Naruhodo, a ciência e o pensamento científico - apoiando financeiramente o nosso projeto de podcast semanal independente, que só descansa no recesso do fim de ano.Manter o Naruhodo tem custos e despesas: servidores, domínio, pesquisa, produção, edição, atendimento, tempo... Enfim, muitas coisas para cobrir - e, algumas delas, em dólar.A gente sabe que nem todo mundo pode apoiar financeiramente. E tá tudo bem. Tente mandar um episódio para alguém que você conhece e acha que vai gostar.A gente sabe que alguns podem, mas não mensalmente. E tá tudo bem também. Você pode apoiar quando puder e cancelar quando quiser. O apoio mínimo é de 15 reais e pode ser feito pela plataforma ORELO ou pela plataforma APOIA-SE. Para quem está fora do Brasil, temos até a plataforma PATREON.É isso, gente. Estamos enfrentando um momento importante e você pode ajudar a combater o negacionismo e manter a chama da ciência acesa. Então, fica aqui o nosso convite: apóie o Naruhodo como puder.bit.ly/naruhodo-no-orelo
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some fascinating updates that are shaping the future of medicine and healthcare.Let's start with a groundbreaking development in cancer treatment. Researchers have announced significant progress in a novel therapy targeting a specific mutation often found in non-small cell lung cancer. This mutation, known as EGFR exon 20 insertion, has historically been resistant to standard treatments. The new therapy employs a targeted approach that precisely inhibits the mutant protein while sparing normal cells. Early-phase clinical trials have shown promising results, with substantial tumor shrinkage observed in participants. This could potentially redefine treatment protocols for patients who previously had limited options and improve their overall survival rates. As the study progresses into later phases, the industry is watching closely to see if these initial successes translate into long-term benefits.In another significant development, we're seeing advancements in gene therapy for inherited retinal diseases. A recent study has highlighted a novel gene-editing technique that promises to restore vision in patients with certain genetic forms of blindness. By utilizing CRISPR-Cas9 technology, scientists have been able to directly correct mutations in retinal cells. The preclinical models have shown restored function and improved visual responses, paving the way for human trials. This breakthrough is not just a beacon of hope for those affected by genetic blindness but also underscores the transformative potential of gene-editing technologies in treating complex diseases.Moving on to regulatory news, there's an update on new drug approvals that could have widespread implications for public health. The FDA has recently approved a first-in-class drug for the treatment of severe migraines. This medication represents a novel mechanism of action by targeting the calcitonin gene-related peptide (CGRP) pathway, which plays a crucial role in migraine pathophysiology. Clinical trials indicated that it significantly reduces the frequency and severity of migraine attacks compared to existing treatments. For millions of sufferers worldwide, this approval offers a new avenue for relief and highlights the importance of continued innovation in chronic pain management.Shifting gears to vaccine development, there's exciting progress in the fight against infectious diseases. A new vaccine candidate for malaria has shown an unprecedented level of efficacy in trial settings. This vaccine utilizes a protein-based approach that targets multiple stages of the parasite's lifecycle, thereby enhancing its protective effects. Given malaria's devastating impact globally, particularly in sub-Saharan Africa, this development is being hailed as a potential game-changer in global health efforts. As further studies and real-world evaluations unfold, this vaccine could become a cornerstone tool in reducing malaria's burden.Now turning our attention to industry trends, there's growing momentum around personalized medicine and its integration into mainstream healthcare systems. Personalized medicine tailors treatment strategies to individual patient profiles based on genetic, environmental, and lifestyle factors. Recent advances in genomics and data analytics have accelerated this shift, allowing for more precise and effective interventions. For healthcare providers and pharmaceutical companies alike, this trend necessitates rethinking traditional drug development models and embracing collaborative approaches to harness big data effectively.Finally, let's look at an intriguing development in neurodegenerative disease research. Scientists are exploring a new class of drugs designed to target protein misfolding—an underlying cause of conditions Support the show
Send us a textWe map a practical path from “is this dangerous?” to “what actually helps." We also talk about some specific headache types such as: IIH, medication overuse, trigeminal neuralgia as well as the rise of CGRP therapies.• separating primary from secondary headache with SNOOP4• recognizing thunderclap, GCA, IIH, and low-pressure patterns• uncovering hidden chronic headache burden and medication overuse• exam essentials including fundoscopy and neck palpation• trigeminal neuralgia in MS and targeted MRI protocols• rescue strategy with effective OTC dosing and triptan timing• antiemetic choices matched to daily function• preventives matched to sleep, anxiety, weight, and goals• carbamazepine and oxcarbazepine for trigeminal neuralgia• role of acetazolamide and topiramate in pressure states• CGRP therapies, access hurdles, and practical selection• empowering patients with education, logs, and portable plansSupport the show Check out our website at www.theneurotransmitters.com to sign up for emails, classes, and quizzes! Would you like to be a guest or suggest a topic? Email us at contact@theneurotransmitters.com Follow our podcast channel on
In this Faces of Digital Health episode Dr. David Dodick, Chief Science and Medical Officer at the Atria Health Institute and Co-Chair of the Atria Research Institute talks about brain health, dementia prevention, the rapidly evolving science of Alzheimer's, and how digital tools and AI are transforming care. We also cover why women face higher Alzheimer's risk, the microvasculature's role in cognition, and the biggest leap in migraine treatment: CGRP-targeting therapies. A must-watch if you're curious about prevention, personalized risk, and which consumer tech is actually useful today. Dr. David Dodick trained at the Mayo Clinic and served on the faculty there for more than three decades. At the Mayo Clinic, he founded the Neurology Residency Program, the Headache Fellowship Program, the Sports Neurology and Concussion Program, the Migraine and Headache Program, and co-founded the Vascular Neurology/Stroke Program. What you'll learn: 1. How much dementia is realistically preventable—and how to lower your risk 2. Why amyloid ≠ destiny, and what “biological vs. clinical” Alzheimer's means 3. The role of sleep, hearing, blood pressure, metabolic health, and social connection 4. Smart wearables that matter (AFib, BP, CGM) and what's just hype 5. How AI “diagnostic orchestrators” could supercharge clinicians and empower patients 6. Migraine red flags (when to go to the ER) and the CGRP revolution in treatment
What if one side of your body suddenly stopped moving — and your doctor said, “It's a migraine”?Hemiplegic migraines are rare, disorienting, and often confused with strokes. They challenge everything you think you know about how your brain, body, and energy connect.In this episode of Migraine Heroes Podcast, hosted by Diane Ducarme, we explore the science and the story behind this rare form of migraine — one that blurs the line between neurology and mystery. Together, we look at how the body can temporarily lose its flow, and how to gently help it find its rhythm again.In this episode, you'll learn:
Drs. Hindiyeh and Hutchinson review new FDA-issued safety warnings for Raynaud's phenomenon and hypertension in CGRP-based migraine treatment. They explore the impact of this label update and share practical strategies for patient management.
People ask me all the time, “Does Botox work for vestibular migraine?” Another common question people ask is, “Is it going to get rid of my dizziness?” That question is missing the point. When you're treating vestibular migraine, you're not treating the dizziness. Does Botox work for VM? Yes, but not because you're treating the dizziness. In this episode, you'll hear me synthesize a study that dove into the impact of Botox on vestibular migraine—how it works, who it works for, and some important things to know if you'd like to explore this treatment for yourself. In this episode, we'll dig into: What is Botox for and not to be used for How Botox treats vestibular migraine Where the Botox injections happen for vestibular migraine If insurance covers Botox for vestibular migraine How many Botox treatments it takes to see any change Important note if you have EDS and VM and are interested in Botox If you think Botox is just freezing the muscles and therefore vestibular migraine goes away—no. As you heard in the episode, there are way deeper things going on. Resources referenced in this episode are linked below, so you can review them on your own and share them with your doctor. Related Episodes: Guide to CGRP Medications for VM Links/Resources Mentioned: Vestibular Group Fit (code GROUNDED at checkout!) https://pmc.ncbi.nlm.nih.gov/articles/PMC10751376/ https://pmc.ncbi.nlm.nih.gov/articles/PMC9358216/#abstract1 Blog: Vestibular Migraine: Popular Symptoms and Treatment Blog: Best 5 Tips for Managing Vestibular Migraine More Links/Resources: The 4 Steps to Managing Vestibular Migraine The PPPD Management Masterclass What your Partner Should Know About Living with Dizziness The FREE Mini VGFit Workout The FREE POTS - safe Workouts Vestibular Group Fit (code GROUNDED at checkout for 15% off your first subscription cycle!) Connect with Dr. Madison: @TheVertigoDoctor @TheOakMethod @VestibularGroupFit Connect with Dr. Jenna @dizzy.rehab.therapist Work with Dr. Madison 1:1, Vestibular Rehabilitation Therapy Vestibular Group Fit Small Group Coaching (offered throughout the year, sign up for our email list to learn when!) Why The Oak Method? Learn about it here! Love what you heard? Reviews really help us out! Please consider leaving one for us. This podcast is for informational purposes only and may not be the best fit for you and your personal situation. It shall not be construed as medical advice. The information and education provided here is not intended or implied to supplement or replace professional medical treatment, advice, and/or diagnosis. Always check with your own physician or medical professional before trying or implementing any information read here. ————————————— botox for vestibular migraine, BPPV, PPPD, Vestibular migraine, VM, constant vestibular migraine, how to treat vestibular migraine, vestibular migraine symptoms, SSRI, will insurance cover Botox for vestibular migraine, is Botox covered by insurance, Botox foundation, vertigo attacks, episodic migraine, CGRP levels, EDS, neck strength protocol, deep cervical neck flexors
Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question. In this special edition of Mind Moments, Patricia Pozo-Rosich, MD, PhD, head of the neurology department at Vall d'Hebron University Hospital, discussed the recent FDA approval of fremanezumab (Ajovy) for pediatric migraine prevention. As a study author on the pivotal phase 3 SPACE trial (NCT03539393), Dr. Pozo-Rosich reflected on the significance of having a proven therapeutic option in a population where placebo responses and lack of evidence have long complicated care. She provided insights on how the trial was designed and the challenges of running pediatric studies, particularly in adolescents. Additionally, she highlighted broader implications for migraine research, including efforts to reduce placebo effects, the role of CGRP pathway inhibition in younger patients, and the future promise of emerging targets such as PACAP antagonists and new toxin formulations. For more of NeurologyLive's coverage of fremanezumab's expanded indication in pediatric migraine, head here: FDA Approves Fremanezumab as First Anti-CGRP Preventive Therapy for Pediatric Episodic Migraine Episode Breakdown: 1:10 – Initial reaction to fremanezumab approval and significant for pediatric migraine care 6:05 – Major clinical insights and takeaways from phase 3 SPACE trial 10:20 – Challenges in pediatric migraine trials and addressing high placebo responses 15:10 – Future directions in migraine therapy, including PACAP-targeting drugs and novel approaches Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/PXM865. CME/MOC/AAPA credit will be available until August 26, 2026.From Migraine Recognition to Relief: Improving Outcomes With Patient-Centered CGRP Antagonist Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.
Dr. Bradley Ong shares early insights from the EMERGE trial, presented at the American Headache Society's 67th Annual Scientific Meeting in June 2025. Show reference: https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.14957
Today on Grounded: The Vestibular Podcast, we are talking all about CGRP medications. These are a class of drugs used to manage migraine attacks. Interestingly, people with migraine have a higher level of CGRP during migraine attacks, but also have a harder time breaking them down for whatever reason. In this episode, we'll dig into: What CGRP medications are How CGRP medications work Generic names of CGRP medications How effective CGRPs are How CGRPs interact with Botox Will insurance cover CGRP medications What step therapy is and how to navigate it If a multi-pronged approach is still worth it Whether you're newly diagnosed, still searching for answers, or supporting someone with VM, this episode was created as a resource for you. Tune in and discover if we're fans of CGRPs over here… or not—and everything you need to know about these medications. Links/Resources Mentioned: Vestibular Group Fit (code GROUNDED at checkout!) More Links/Resources: The 4 Steps to Managing Vestibular Migraine The PPPD Management Masterclass What your Partner Should Know About Living with Dizziness The FREE Mini VGFit Workout The FREE POTS - safe Workouts Vestibular Group Fit (code GROUNDED at checkout for 15% off your first subscription cycle!) Connect with Dr. Madison: @TheVertigoDoctor @TheOakMethod @VestibularGroupFit Connect with Dr. Jenna @dizzy.rehab.therapist Work with Dr. Madison 1:1, Vestibular Rehabilitation Therapy Vestibular Group Fit Small Group Coaching (offered throughout the year, sign up for our email list to learn when!) Why The Oak Method? Learn about it here! Love what you heard? Reviews really help us out! Please consider leaving one for us. This podcast is for informational purposes only and may not be the best fit for you and your personal situation. It shall not be construed as medical advice. The information and education provided here is not intended or implied to supplement or replace professional medical treatment, advice, and/or diagnosis. Always check with your own physician or medical professional before trying or implementing any information read here. ————————————— vestibular migraine, VM, CGRP medications, CGRPs for migraine, calcitonin gene-related peptides, migraine disorder, migraine attacks, preventative CGRP, acute CGRP, Aimovig, Ajovy, CGRP injections, Vyepti, Ubrelvy, oral CGRP, are CGRPs covered by insurance, step therapy, comprehensive migraine treatment
Story at-a-glance Women with chronic migraines and body-wide pain were far more likely to have poor oral health, with over half falling into the lowest oral health categories in a new study Specific oral bacteria, including Mycoplasma salivarium and Gardnerella vaginalis, were significantly more common in women who reported frequent migraines and widespread pain Harmful oral microbes don't stay in your mouth; once gum tissue is inflamed, these bacteria enter your bloodstream, disrupt the immune system, and trigger systemic pain A less diverse oral microbiome was found in women with migraines and gut pain, making it easier for pain-triggering bacteria to dominate and inflame nerve pathways Inflammatory chemicals produced by oral bacteria — like calcitonin gene-related peptide (CGRP) and vascular endothelial growth factor (VEGF) — are directly involved in migraine and fibromyalgia, showing how poor oral hygiene can set off whole-body pain responses
© 2020-2026 Ivy Podcast Discovery LLC
